Cubist Systematic Strategies’s ZyVersa Therapeutics ZVSA Stock Holding History

Cubist Systematic Strategies’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,937	Closed	-$22K	–	4180
2024 Q1	$22K	Buy	+2,937	New	+$22.1K	﹤0.01%	3467
2023 Q3	–	Sell	-105	Closed	-$9.05K	–	4016
2023 Q2	$9.05K	Buy	+105	New	+$27.6K	﹤0.01%	3267
2022 Q4	–	Sell	-714	Closed	-$2.5M	–	4651
2022 Q3	$2.5M	Buy	714 +564	+376%	+$1.97M	0.01%	1776
2022 Q2	$521K	Buy	+150	New	+$521K	﹤0.01%	3029

Other funds holding ZVSA

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cubist Systematic Strategies's ZVSA Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of ZyVersa Therapeutics (ZVSA) in Q2 2024, closing a stake of 2,937 shares — an estimated $22K sold.

Cubist Systematic Strategies first reported a position in ZVSA in Q2 2022 and held it in 4 quarters. The position peaked at $2.5M in Q3 2022. 4 funds tracked by Wall St. Rank hold ZVSA as of Q2 2024.

Cubist Systematic Strategies reported no remaining ZyVersa Therapeutics position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 2,937 ZyVersa Therapeutics shares in Q2 2024, an estimated $22K.
Cubist Systematic Strategies first reported a position in ZyVersa Therapeutics in Q2 2022 and held it in 4 quarters.
Cubist Systematic Strategies's ZyVersa Therapeutics position peaked at $2.5M in Q3 2022.
4 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.